Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


  • Diabetes Mellitus (type 1 or 2)
  • Male or Female
  • No diagnosed occlusive arterial disease
  • Aged >= 40 years


  • Potentially eligible patients identified from existing diabetes registers and databases
  • Permission sought from GP to approach suitable individuals
  • Invitation letter sent (by GP or Diabetologist) with Information Leaflet, Consent Form and brief Screening Questionnaire (& central Freefone number for any questions)


  • Screening Questionnaire returned, which identifies eligible and consenting patients
  • Run-in pack with 2-month supply of treatment mailed to patient
  • GP informed of patient's possible participation, and asked to return form if patient not to be randomised
  • Blood and urine samples (optional) collected locally and mailed to central laboratory
  • Freefone number for medical advice and any questions


  • Randomisation Questionnaire sent to re-confirm eligibility, and to characterize the patient more fully
  • Randomisation Questionnaire returned, and eligible patient randomised by central computer
  • Allocated treatment pack mailed to patient: 100 mg aspirin daily or matching placebo tablet, and 1g omega-3 FA daily or matching placebo capsule
  • GP informed of patient's randomisation


  • Follow-up Questionnaires and treatment packs sent 6-monthly
  • Freefone number for medical advice and any questions
  • Further details sought from responsible clinicians about any relevant events reported on Follow-up questionnaires
  • Flagging for mortality and cancer at central registries